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BACKGROUND: We recently identified matrix extracellular phosphoglycoprotein/osteoblast factor 45 (MEPE/OF45) as a new cofactor
of CHK1 in rat cells. The aim of this study was to determine the role of human MEPE/OF45 (hMEPE/OF45 hasB50% homology with
rat MEPE/OF45 (rMEPE/OF45)) in affecting the sensitivity of human tumour cells to DNA damage.
METHODS: hMEPE/OF45 expression in different human tumour cell lines and its relevance to the resistance of cell lines to
DNA damage inducers such as ionising radiation (IR) or camptothecin (CPT) were assessed. Cells lines stably expressing wild-type
MEPE/OF45 or mutant MEPE/OF45 (with the CHK1 interactive key domain (amino acids 488–507) deleted) were established.
Cell survival, G2 accumulation, CHK1 half-life and the CHK1 level in ligase 3 complexes were examined.
RESULTS: hMEPE/OF45 expression correlates with the resistance of cell lines to IR or CPT. Upregulating wild-type hMEPE/OF45
(but not mutant hMEPE/OF45) could stabilize CHK1 by reducing CHK1 interaction for its E3 ligases Cul1 or Cula4A; it increases the
G2 checkpoint response and increases the resistance of tumour cells to IR or CPT treatment.
CONCLUSION: hMEPE/OF45 could be a new target for sensitizing tumour cells to radiotherapy or chemotherapy.
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Matrix extracellular phosphoglycoprotein/osteoblast factor 45
(MEPE/OF45) was originally cloned from a human oncogenetic
hypophosphataemia tumour (Rowe et al, 2000) and then identified
in rat bone-marrow-derived osteoblasts (Petersen et al, 2000). The
murine homologue of MEPE/OF45 was reported the following year
(Argiro et al, 2001). Since the identification of MEPE/OF45, its
function related to bone metabolism has been widely investigated.
We previously identified that MEPE/OF45, as a cofactor of CHK1,
protects cells from DNA damage-induced killing in rat embryo
fibroblast cells (Liu et al, 2009). However, because human MEPE/
OF45 (hMEPE/OF45) has only B50% homology with rat MEPE/
OF45 (rMEPE/OF45), it remained unclear whether hMEPE/OF45
has similar function to rMEPE/OF45.
CHK1 is one of the essential checkpoint proteins involved in
cellular response to multiple DNA damage inducers (Liu et al,
2000; Zhao et al, 2002). It is believed that upregulated CHK1
protects cells from DNA damage-induced cell killing, including
that induced by ionising radiation (IR) and camptothecin (CPT)
(Hu et al, 2001, 2005a; Zhao et al, 2002; Wang et al, 2002b; Brown
and Baltimore, 2003), by promoting homologous recombination
repair (HRR) (Sorensen et al, 2005; Hu et al, 2005b). Despite the
importance of CHK1 in DNA damage response, the regulation of
CHK1 in mammalian cells is not well understood, partly because of
its essential nature (Liu et al, 2000; Lam et al, 2004).
In this study, on the basis of our previous report about the new
role of rMEPE/OF45 in protecting cells from DNA damage-induced
killing (Liu et al, 2009), we investigate whether hMEPE/OF45 is
generally expressed in different types of tumour cells, whether the
expression levels were relevant to the resistance of tumour cells to
DNA damage inducers and whether, similar to rMEPE/OF45,
hMEPE/OF45 (as a cofactor of CHK1) could be a new target for
sensitizing human tumour cells to DNA damage inducers.
MATERIALS AND METHODS
Cell lines and antibodies
All human tumour cell lines used in this study were derived from
ATCC. These cell lines were grown in DMEM medium supple-
mented with 10% calf serum. The antibody against hMEPE/OF45
was as described (Rowe et al, 2000, 2004). Purified HA-tagged
JNK2 protein (sc-4062) and antibodies against CHK1 (sc-8408
and sc-7898), HA (sc-805, sc-7392), PCNA (sc-56), a-Tubulin
(sc-8035), Cul4 (sc-10782) and ubquitin (Ub) (sc-9133) were
purchased from Santa Cruz Biotechnology Inc (Santa Cruz, CA,
USA). The antibody against Cul1 was purchased from Zymed
Laboratories (San Francisco, CA, USA) and the antibody against
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H2A (07-146) was purchased from Upstate Biotechnology (Lake
Placid, NJ, USA).
Plasmid construction and transfection
The full-length cDNA of wild-type hMEPE/OF45 or mutant
hMEPE/OF45 (with the sequence encoding 488–507 amino acids
(aa) deleted) was ligated with HA tag at the C terminus by PCR.
hMEPE/OF45 was then cloned into pLenti6/V5-D-TOPO vector
(Invitrogen), according to the manufacturer’s protocol. The HA tag
was inserted into the plasmid. The primers used for wild-type
hMEPE/OF45 are: forward, 50-CACCATGGGAGTTTTCTGTGTGG
GACTACTCCTTTTCAGTGTGACCTG-30 and reverse, 50-AGGTCC
TCCCAGGCTGGCATAGTCAGGCACGTCATAAGGATAGTCACCA
TCGCTCTCACTTGAAC-30. The procedure to construct mutant
hMEPE/OF45 has been described in Supplementary Figure S1. The
primers for fragment 1 (1–477 aa) are F1, ACGGATCCATGCGA
GTTTTCTGTGTGGGACTACTCC and R1, TACTGTCATCCTTATT
CCGTGTAGA, and for fragment 2 (507–514 aa) are F2, ACGGAAT
AAGGATGACAGTAGTGAGTCATC and R2, AAGAATTCGTCACC
ATCGCTCTCACTTG. For lentivirus production, pLenti6/V5-D-
TOPO was co-transfected with packaging vectors into human 293
cells and the supernatant was harvested after 48 h. The virus was
filtered through a Millex-HV PVDF filter (hole diameter: 0.45 mM).
Titres were determined by infecting 293 cells with a serial dilution
of the concentrated virus. For a typical preparation, the titre was
approximately 2- to 7 104 TUml1. For infection of 293 cells,
30–50% confluent cells were incubated with a suitable amount
of virus particles and 10 mgml1 polybrene for 8–16 h at 371C.
A volume of 10 mgml1 of blasticidin (Invitrogen) was used to
select stably expressed cells.
Immunoprecipitation
Immunoprecipitation was performed as described previously
(Wang et al, 2002a). The samples were washed with buffer
(0.5% NP-40, 1mM Na3VO4, 5mM NaF and 0.2mM PMSF in
PBS buffer) and boiled in 30 ml of protein loading buffer. They
were loaded onto 10% Tris-PAGE gel, followed by the standard
western blot.
Cell sensitivity to DNA damage inducers and flow
cytometry measurement
Cell sensitivity to IR or to CPT was determined by clonogenic
assay as described previously (Hu et al, 2001; Wang et al, 2002b).
The G2 accumulation of cells after radiation was detected by flow
cytometry as described previously (Hu et al, 2001). Briefly, 2 105
cells were plated in 60mm dishes, with 3ml of growth medium.
After 30 h, the cells were exposed to 6Gy and returned to 371C.
At different times thereafter, the cells were trypsinised and fixed
in 70% ethanol. Cells were stained in solution (62mgml1 RNase A,
40 mgml1 propidium iodide and 0.1% Triton X-100 in PBS
buffer) at room temperature for 1 h. The distribution of cells in the
cell cycle was measured using a flow cytometer (Coulter Epics
Elite, Beckman Coulter Inc., Atlanta, GA, USA).
Statistical analysis
Differences between treatment groups were analysed using statis-
tical software (t-test). P-valueso0.05 were regarded as significant.
RESULTS AND DISCUSSION
MEPE/OF45 presents in all kinds of human dividable cell
lines tested in our laboratory
We previously identified that rMEPE/OF45 could protect rat cells
from DNA damage-induced killing (Liu et al, 2009). However,
because the amino-acid sequence of hMEPE/OF45 (525 amino
acid) has B50% homology compared with that of rMEPE/OF45
(435 amino acid) (Argiro et al, 2001), it remained unclear whether
hMEPE/OF45 has a function similar to rMEPE/OF45. To investi-
gate whether MEPE/OF45 was important for human cells to
respond to DNA damage, we examined the MEPE/OF45 expression
level in different human cell lines, including primary fibroblast
cells, transformed fibroblast cells, transformed lymphoblast cells
and tumour cell lines from different human tissues. These cell lines
all showed a positive expression of MEPE/OF45, although the levels
of expression varied (Figure 1A), indicating that MEPE/OF45
expresses in replicating cells. The signals of human MEPE/OF45
showed two bands (Figure 1A), which might be due to alternatively
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Figure 1 MEPE/OF45 expressed in dividable human cells. (A) Whole-cell lyses were prepared. The antibody against hMEPE/OF45 was as described
(Rowe et al, 2000, 2004). Data shown are the images of western blot analysis. Expression of MEPE/OF45 in human normal and tumour cell lines. 1, purified
MEPE/OF45 protein (Rowe et al, 2000); 2, MRC5 (primary human fibroblast); 3, MRC5-SV1 (transformed MRC5); 4, C3-ABR (transformed human
lymphoblasts); 5, HeLa (human cervical cancer); 6, HCC1937 (breast cancer); 7, U87MG glioblastoma; 8, SAOS2 (osteosarcoma); 9, HT-29 (colorectal
cancer); 10, A549 (lung carcinoma); 11, PC-3 (prostate cancer); 12, HT-144 (melanoma); 13, 293 (kidney cancer); 14, SQ20B (laryngeal cancer); 15, Capan-1
(pancreatic cancer); 16, OVCAR10 (ovarian adenocarcinoma); 17, MCF-7 (breast cancer). (B) Sensitivities of different human cell lines to DNA damage
inducers. The sensitivities of cell lines to various doses of IR or CPT exposure (24 h) were examined using clonogenic assay. Bars show the mean±s.e. of the
percentage of colonies from non-treated control cells. Data were obtained from three independent experiments.
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spliced MEPE/OF45s. Our group recently identified a new exon of
hMEPE/OF45 between formerly identified exons 3 and 4 (GenBank
accession no. DQ854717). The functions of the different forms of
MEPE/OF45 need to be investigated further. Interestingly, the
levels of MEPE/OF45 in different human tumour cell lines
broadly correlate with the resistance of cell lines to DNA damage
inducers (Figure 1B). The higher the level of MEPE/OF45 was in
the cell line, the more resistant the cell line was to IR or CPT. There
were 293 cells with the lowest level of MEPE/OF45, and they were
most sensitive to IR or CPT. In addition, we reported that knocking
down MEPE/OF45 could sensitise HeLa cells to DNA damage inducers
(Liu et al, 2009). These results indicate that MEPE/OF45 protects
human cells from DNA damage-induced killing.
Human MEPE/OF45 interacts with CHK1 and stabilises CHK1
We previously reported that rMEPE/OF45 protected cells from
DNA damage-induced killing through its interaction with CHK1
(Liu et al, 2009). We wanted to determine whether similar to
rMEPE/OF45, hMEPE/OF45 could also interact with CHK1. To
study the relationship of hMEPE/OF45 with CHK1, we first
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Figure 2 MEPE/OF45 interacts with CHK1 and stabilises CHK1. (A) Whole-cell lyses were prepared from HeLa cells. Signals were detected
from immunoprecipitation (IP) results. Lanes 1 and 2 show the results from IP experiments that used general mouse or rabbit serum as the negative
controls. Lane 3 indicates the western blot signals of CHK1 or of MEPE/OF45 from MEPE/OF45 or CHK1 antibody– immunoprecipitated complex. (B) Left:
the corresponding amino-acid sequence of rMEPE/OF45 (400–418) in hMEPE/OF45 is 490–507. Right: MEPE/OF45 interacts with CHK1 in human
293 cell lines. Western blot (IB) with CHK1 or with MEPE/OF45 antibody was used to detect the signals of MEPE/OF45 interacting with CHK1 from
CHK1 or HA immunoprecipitated (IP) samples. V1: 293 cells transfected with vector alone; W1–W3: 293 cells transfected with wild-type hMEPE/OF45;
D1–D2: 293 cells transfected with mutant hMEPE/OF45 (amino acid 490–507) deleted. (C) CHK1 half-life in different cell lines: cells were treated with
100 mgml1 CHX at different times. Whole-cell lyses were prepared. CHK1 signals were detected by western blot. The CHK1 levels were plotted using
PhosphorImager (GE Healthcare Bioscience Corp., Piscataway, NJ, USA) with software (ImageQuant). (D) MEPE/OF45 affects CHK1 interacting with
E3 ligases in human cells. Extracts were prepared from these cells using an NE-PER kit (Pierce, Rockford, IL, USA). The extracts (500 mg of cytoplasmic
extracts or 300 mg of nucleic extracts) were mixed with protein A that was conjugated with Cul1 or Cul4 antibody for IP. CHK1 antibody was used for
immunoblotting. H2A or a-tubulin was used as an indicator for nuclear or cytoplasmic extracts.
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synchronised HeLa cells and examined the expression of MEPE/
OF45 at different phases of the cell cycle, as CHK1 expression
depends on the cell cycle (Kaneko et al, 1999). The results showed
that similar to CHK1, MEPE/OF45 expressed low in the G1 phase
and high in the S and G2 phases (Supplementary Figure S2),
suggesting a correlation between these two proteins. We further
examined the interaction between hMEPE/OF45 and CHK1 using
an immunoprecipitation (IP) approach in HeLa cells. The results
showed that, similar to rMEPE/OF45, hMEPE/OF45 also interacted
with CHK1 (Figure 2A). The key domain of rMEPE/OF45 was
400–418 amino acids (Liu et al, 2009). The corresponding amino-
acid sequence in hMEPE/OF45 is 490–507 (Argiro et al, 2001;
Figure 2B, left). To study whether CHK1 was stabilised when inter-
acting with hMEPE/OF45, as it was when interacting with rMEPE/
OF45, we generated the constructs encoding HA-tagged either
wild-type hMEPE/OF45 or mutant hMEPE/OF45 with amino acid
488–507 deleted (Supplementary Figure S1). We expressed the
wild-type hMEPE/OF45 or mutant hMEPE/OF45 in 293 cells, as
this cell line had the lowest level of MEPE/OF45 in the human
tumour cell lines tested in our laboratory (Figure 1A). The results
showed that wild-type hMEPE/OF45 but not mutant hMEPE/OF45
could interact with CHK1 (Figure 2B, right), indicating that the
488–507 amino acids are the key domain for hMEPE/OF45 to
interact with CHK1.
We were then interested in determining whether similar to
the key domain of rMEPE/OF45, the key domain of hMEPE/OF45
also had an essential role in stabilising CHK1 by reducing the
interaction of CHK1 for its E3 ligases, Cul1 or Cul4A. For this, we
first compared the half-life of CHK1 between wild-type
hMEPE/OF45-expressing cells and mutant hMEPE/OF45-expres-
sing cells.
The results showed that the half-life of CHK1 in the wild-type
hMEPE/OF45-expressing cells (W1) is longer than that in parental
cells (293), the 293 cells transfected with the vector alone (V1)
and the 293 cells transfected with mutant hMEPE/OF45 (D1)
(Figure 2C). These results indicate that the interaction domain is
essential for hMEPE/OF45 to stabilise CHK1. We then compared
the CHK1 levels in its E3 ligase complexes with wild-type hMEPE/
OF45-expressing cells and mutant hMEPE/OF45-expressing cells.
Results showed that although the total levels of CHK1 in either
cytoplasmic extracts (CE) or nuclear extracts (NE) are similar to all
types of cells (293, V1, D1 and W1), the CHK1 levels in Cul1 or
Cul4A IP complexes in W1 cells were less than that in 293, V1 or
D1 cells (Figure 2D). Additional data showed that when hMEPE/
OF45 was knocked down, ubiquitinated CHK1 was increased
(Supplementary Figure S3A and B). These results indicate that
although hMEPE/OF45 has B50% homology with rMEPE/OF45,
its C-terminal amino-acid sequence, including the key domain to
interact with CHK1, is relatively conserved, and similarly functions
to stabilise CHK1.
Wild-type but not mutant hMEPE/OF45 renders tumour
cells resistant to DNA damage inducers
To further examine whether hMEPE/OF45 was similar to rMEPE/
OF45, and could protect cells from DNA damage-induced killing
through interaction with CHK1, we compared the effects of wild-
type hMEPE/OF45 and mutant hMEPE/OF45 on the G2 checkpoint
response and the sensitivity of 293 cells to DNA damage inducers.
The results showed that wild-type hMEPE/OF45 could increase the
G2/M accumulation of cells after IR, but not mutant hMEPE/OF45
(Figure 3A). Similarly, knocking down hMEPE/OF45 reduced
IR-induced G2 accumulation (Supplementary Figure S3A and C).
These results further support that hMEPE/OF45 functions through
the CHK1 pathway to affect cell response to DNA damage, because
this kind of checkpoint response, G2-phase cell accumulation, is
ATM independent (Xu et al, 2002) but CHK1 dependent (Wang
et al, 2003). More importantly, the results showed that wild-type
hMEPE/OF45 could increase resistance of the cells to either IR
or CPT treatment, but not mutant hMEPE/OF45 (Figure 3B). The
P-values between 293W (including 1 and 2) and other groups are
o0.01. These results indicate that hMEPE/OF45 protects cells from
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Figure 3 Upregulating wild-type MEPE/OF45 but not mutant MEPE/OF45 deleted the key domain that interacted with CHK1, making the tumour cells
resistant to DNA damage inducers. (A) Comparison of the G2 accumulation of 293 cell lines (293, 293V1, 293W1 and 293D1) at different times after IR
(6Gy). The P-values between 293W (including 1 and 2) and other groups are o0.01. (B) Comparison of the sensitivities of 293, 293V1, 293W1, 293D1
and 293W2 cells to IR or CPT treatment (16 h). Data represented the average of three independent experiments and were expressed as the percentage of
cell colonies without treatment. Data were obtained from three independent experiments.
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DNA damage-induced killing depending on its interaction with
CHK1. It is known that CHK1 promotes HRR through regulation
of checkpoint activation (Sorensen et al, 2005; Hu et al, 2005b). We
believe that hMEPE/OF45 increases the CHK1 level by stabilising
CHK1, which promotes HRR and protects cells from DNA damage-
induced killing.
CONCLUSION
Taken together, the results of our study indicate that MEPE/OF45
protecting human cells from IR- or CPT-induced killing mainly
depends on its interaction with CHK1. The specific molecular
mechanism for this protective role of MEPE/OF45 could be
linked to MEPE/OF45 stabilising CHK1 by reducing CHK1
degradation. Because CHK1 is an essential gene (Liu et al, 2000;
Lam et al, 2004) and MEPE/OF45 is not (Gowen et al, 2003), our
study results indicate that MEPE/OF45 is a new cofactor of CHK1,
which could be a new target with less side effects for sensitizing
tumour cells to DNA damage inducers and could benefit cancer
treatment.
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